PDF(Pubmed)
Abstract：
UNASSIGNED: To verify our hypothesis that psoriatic arthritis (PsA) is mainly genetically predetermined and distinct from psoriasis (PsO), we use the TriNetX database to investigate whether intrinsic factors outweigh externals in PsA emergence in PsO patients.
UNASSIGNED: We conducted three retrospective cohort studies utilizing information from the TriNetX network, whether (a) PsO patients with type 2 diabetes mellitus (DM) face an elevated risk of developing PsA compared to those without type 2 DM; (b) PsO patients who smoke face a higher risk of PsA; and (c) PsO patients with type 2 DM who smoke are more likely to develop PsA than those who do not smoke.
UNASSIGNED: PsO patients with type 2 DM exhibited an elevated risk of developing PsA [hazard ratio (HR), 1.11; 95% CI 1.03-1.20], with the combined outcome demonstrating a heightened HR of 1.31 (95% CI 1.25-1.37). PsO patients with a smoking history exhibited an elevated risk of developing PsA (HR, 1.11; 95% CI 1.06-1.17), with the combined outcome demonstrating a heightened HR of 1.28 (95% CI 1.24-1.33). PsO patients with type 2 DM and a history of smoking were not found to be associated with an increased risk of developing PsA (HR, 1.05; 95% CI 0.92-1.20). However, the combined result revealed a higher risk of 1.15 (95% CI 1.06).
UNASSIGNED: These findings suggested that intrinsic factors outweigh external factors in PsA emergence in PsO patients. Further studies may focus on genetic disparities between PsO and PsA as potential risk indicators rather than solely on phenotypic distinctions.
UNASSIGNED: We conducted three retrospective cohort studies utilizing information from the TriNetX network, whether (a) PsO patients with type 2 diabetes mellitus (DM) face an elevated risk of developing PsA compared to those without type 2 DM; (b) PsO patients who smoke face a higher risk of PsA; and (c) PsO patients with type 2 DM who smoke are more likely to develop PsA than those who do not smoke.
UNASSIGNED: PsO patients with type 2 DM exhibited an elevated risk of developing PsA [hazard ratio (HR), 1.11; 95% CI 1.03-1.20], with the combined outcome demonstrating a heightened HR of 1.31 (95% CI 1.25-1.37). PsO patients with a smoking history exhibited an elevated risk of developing PsA (HR, 1.11; 95% CI 1.06-1.17), with the combined outcome demonstrating a heightened HR of 1.28 (95% CI 1.24-1.33). PsO patients with type 2 DM and a history of smoking were not found to be associated with an increased risk of developing PsA (HR, 1.05; 95% CI 0.92-1.20). However, the combined result revealed a higher risk of 1.15 (95% CI 1.06).
UNASSIGNED: These findings suggested that intrinsic factors outweigh external factors in PsA emergence in PsO patients. Further studies may focus on genetic disparities between PsO and PsA as potential risk indicators rather than solely on phenotypic distinctions.
摘要：
■为了验证我们的假设，银屑病关节炎（PsA）主要是遗传预先确定的，与银屑病（PsO）不同，我们使用TriNetX数据库调查PsO患者PsA出现的内在因素是否大于外在因素.
■我们利用TriNetX网络的信息进行了三项回顾性队列研究，是否(a)2型糖尿病(DM)的PsO患者患PsA的风险高于无2型DM的患者;(b)吸烟的PsO患者患PsA的风险较高;(c)吸烟的2型DM患者患PsA的风险高于不吸烟的患者.
■患有2型DM的PsO患者出现PsA[危险比（HR），1.11；95%CI1.03-1.20]，合并结果显示HR升高为1.31(95%CI1.25-1.37)。有吸烟史的PsO患者出现PsA的风险升高(HR，1.11；95%CI1.06-1.17），合并结果显示HR升高为1.28（95%CI1.24-1.33）。未发现2型DM和吸烟史的PsO患者与发展PsA的风险增加有关（HR，1.05；95%CI0.92-1.20）。然而,综合结果显示，风险较高，为1.15（95%CI1.06）。
■这些研究结果表明，PsO患者出现PsA的内在因素大于外部因素。进一步的研究可能集中在PsO和PsA之间的遗传差异作为潜在的风险指标，而不仅仅是表型差异。
■我们利用TriNetX网络的信息进行了三项回顾性队列研究，是否(a)2型糖尿病(DM)的PsO患者患PsA的风险高于无2型DM的患者;(b)吸烟的PsO患者患PsA的风险较高;(c)吸烟的2型DM患者患PsA的风险高于不吸烟的患者.
■患有2型DM的PsO患者出现PsA[危险比（HR），1.11；95%CI1.03-1.20]，合并结果显示HR升高为1.31(95%CI1.25-1.37)。有吸烟史的PsO患者出现PsA的风险升高(HR，1.11；95%CI1.06-1.17），合并结果显示HR升高为1.28（95%CI1.24-1.33）。未发现2型DM和吸烟史的PsO患者与发展PsA的风险增加有关（HR，1.05；95%CI0.92-1.20）。然而,综合结果显示，风险较高，为1.15（95%CI1.06）。
■这些研究结果表明，PsO患者出现PsA的内在因素大于外部因素。进一步的研究可能集中在PsO和PsA之间的遗传差异作为潜在的风险指标，而不仅仅是表型差异。
